AstraZeneca invests in Imperial’s self-amplifying RNA technology with eye on future drugs

0 20

AstraZeneca has struck a deal with the firm behind Imperial College London’s experimental Covid-19 vaccine.

Leave A Reply

Your email address will not be published.